🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#CCCF2021 Keynote address Monday December 6, 4:45pm Anticoagulation in COVID-19 by Ryan Zarychanski Ewan Goligher @PatrickLawlerMD criticalcarecanada.com

Ewan Goligher @PatrickLawlerMD and Ryan Zarychanski present the results of the ATTACC trial, platform trials and the global collaboration involved CCCF #CCCF2021 with John Granton and Charlotte Summers

A step forward - therapeutic LWMH recommended for hospitalized non-critically I’ll patients with COVID19 @PatrickLawlerMD Ewan Goligher @ATTACC_COVID remap-cap ACTIV4a Critical Care Reviews CHEST World Health Organization (WHO)

Practice changing work from the #mpRCT and efforts of ACTIV4a @ATTACC_COVID remap-cap. @nih_nhlbi NIH guidelines recommending therapeutic heparin for moderately ill hospitalized patients with #Covid_19 based on our NEJM papers @NIHCOVIDTxGuide UPMC University of Pittsburgh

🔥 This week we'll be discussing the hot topic of VTE Prophylaxis in COVID-19 ‼️ Our latest protocol is published on Ask Mayo Expert (AME): mayocl.in/35QZcJu Go to Inpatient management (adult) ➡️ Inpatient care ➡️ COVID-19 VTE Prophylaxis in Hospitalized Patients

Thanks to the authors of these 6 high quality RCTs we were able to document that full anticoagulation is improving survival in non-critically-ill #covid19 Swiss COVID-HEP #PROTHROMCOVID @ATTACC_COVID ACTIV4a remap-cap #RAPIDtrial COVID-HEP BEMICOP 🔗 link.springer.com/article/10.100…

ATTACC PI Dr. Ryan Zarychanski is being recognized as Doctors Manitoba Physician of the Year. Congratulations Ryan Zarychanski! We look forward to your leadership in the next chapter of the ATTACC trial.

We are pleased to announce an investment of $500K allocated over 5 years designated to support the ATTACC-CAP trail led by University of Manitoba researcher Ryan Zarychanski, this will be the second-largest clinical trial led out of Manitoba. Read full news release: bit.ly/44gf40Q

Our next phase of ATTACC, ATTACC-CAP, has been generously funded by Research Manitoba! Congratulations to our Manitoba PIs Ryan Zarychanski and Sylvain Lother, MD

Honored to be recognized as Doctors Manitoba top 40 under 40! This represents the efforts of a large research team - through COVID and now beyond…. It’s thanks to a productive and enabling team and mentors that we can innovate in medicine, for the benefits of our patients.

Thanks to @N2Canada for creating this infographic all about #InternationalClinicalTrialsDay!

200 patients enrolled in ATTACC-CAP!! 💯 💯 Thanks to all our patient participants, their families, our sites, investigators, coordinators, and large number of partners! ATTACC CAP

Such an exciting milestone!

▶️ In Module 4 of our adaptive #clinicaltrial designs series Sofia S. Villar, carole mitnick, Matteo Cellamare, Lorenzo Guglielmetti & Scott Berry present 2 types of adaptive randomisation & 4 case studies: endTB I-SPY 2 remap-cap ATTACC CAP. Watch it 👉🏼 ecraid.eu/news/module-4-…

Today, Minister of Health Mark Holland announced a $43M investment in 14 new Canadian-led #ClinicalTrials to assess treatments and tools with the potential to save lives. canada.ca/en/institutes-…

Congrats to the UM team awarded $6.9 million by the CIHR to lead an international trial of a steroid drug for pneumonia. The grant will enable expansion of a network of hospital-ward research sites, helping Canada prepare for future pandemics. news.umanitoba.ca/um-team-receiv…

We are so excited to expand ATTACC-CAP to include corticosteroids with the introduction of the newly funded DEFEND-CAP domain!

Winnipeg-based research project testing out pneumonia treatment winnipeg.ctvnews.ca/winnipeg-based…